Eye Patch Therapy for Central Serous Retinopathy (CSR)

checkorphan
Learn more about:
Central serous chorioretinopathy
Related Clinical Trial
Eplerenone Versus PDT: Comparative Study by OCTA Pilot Study on Deep Learning in the Eye Panmacular Versus Minimal Micropulse Laser Therapy in Central Serous Chorioretinopathy OCT in Rare Chorioretinal Diseases Evaluation of the Precision of the Microperimetry Function of the Spectral OCT/SLO Selective RPE Laser Treatment (SRT) for Various Macular Diseases Selective Retinal Pigment Epithelium Laser Therapy for Macular Disease of the Retina Non-damaging Retinal Laser Therapy With PASCAL Laser for Macular Diseases Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy Photodynamic Therapy Using Verteporfin for Treatment of Chronic Central Serous Chorioretinopathy (CSC) Eye Patch Therapy for Central Serous Retinopathy (CSR) Multimodal Imaging in Central Serous Chorioretinopathy PRedictive Factors and Changes From Treatment in iPCV Versus CSR Versus nAMD With afLibercept Microperimetric Evaluation After Half-dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone For the Treatment of Chronic Central Serous Chorioretinopathy Pseudo-PDT in Central Serous Chorioretinopathy Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD Bevacizumab Versus Micropulse in Central Serous Chorioretinopathy (CSC) Study of Photodynamic Therapy (PDT) in Patients With Central Serous Chorioretinopathy (CSC) Selective Retina Therapy With Real-Time Feedback-Controlled Dosimetry for Treating Acute Idiopathic Central Serous Chorioretinopathy in Korean Patients Selective Retina Therapy (SRT) in Patients With Idiopathic Central Serous Retinopathy Effects of OCTA-guided PDT in Acute CSC Efficacy and Safety of Intravitreal Aflibercept Injection for Subacute Central Serous Chorioretinopathy Photodynamic Therapy Versus Eplerenone: Treatment Trial for Chronic Central Serous Chorioretinopathy Micropulse 577nm Laser vs Traditional Laser Treatment in Central Serous Chorioretinopathy The Changes of Retinal Capillaries After Half-dose PDT Measured by OCTA in Eyes With CSC Ranibizumab Versus Low-fluence Photodynamic Therapy in the Treatment of Chronic Central Serous Chorioretinopathy Treatment Trial for Acute Central Serous Chorioretinopathy The Safety & Efficacy of Intravitreal Aflibercept Injection in Patients With Persistent Central Serous Chorioretinopathy Eplerenone Treatment for Chronic Central Serous Chorioretinopathy in Hungarian Population A Pilot Study of the Treatment of Central Serous Chorioretinopathy With Ketoconazole Selective Retina Therapy With ‘R:GEN’ in Patients With Central Serous Chorioretinopathy 577nm Micropulse Laser vs Half-dose Photodynamic Therapy on Acute Central Serous Chorioretinopathy Central Serous Chorioretinopathy: Etiology, Course and Prognosis A Study of the Beneficial Effects of Eplerenone on Central Serous Chorioretinopathy Treatment of Chronic Central Serous Chorioretinopathy Via Electromagnetic Stimulation and Platelet- Rich Plasma Brinzolamide for the Treatment of Chronic Central Serous Chorioretinopathy The Effect of Therapy With Bevacizumab in Chronic Central Serous Chorioretinopathy Eplerenone for the Treatment of Central Serous Chorioretinopathy Micropulse Diode Laser Treatment for Chronic Central Serous Chorioretinopathy Comparison of Multifocal Electroretinogram Assessment in Chronic Central Serous Chorioretinopathy (CSC) Between Laser Treatment Group and Photodynamic Therapy Group in Chronic Central Serous Chorioretinopathy Study on the Use of Micropulse Laser to Treat Central Serous Chorioretinopathy Optical Coherence Tomography Angiography (OCT-A) and Central Serous Chorioretinopathy (CSC) Intravitreal Ranibizumab Treatment of Central Serous Chorioretinopathy Effect of Helicobacter Pylori Treatment on Idiopathic Central Serous Chorioretinopathy (ICSCR) Treatment of Chronic Central Serous Chorioretinopathy With Open-Label Anecortave Acetate Short-Term Oral Mifepristone for Central Serous Chorioretinopathy Methotrexate for Central Serous Chorioretinopathy Treatment Trial Central Serous Chorioretinopathy Treated by Modified Photodynamic Therapy Prospective Randomized Controlled Treatment Trial for Chronic Central Serous Chorioretinopathy The Safe Effective Light Dose of Photodynamic Therapy for Chronic Central Serous Chorioretinopathy Eplerenone for Central Serous Chorioretinopathy High-dose Antioxidants for Central Serous Chorioretinopathy

Brief Title

Eye Patch Therapy for Central Serous Retinopathy (CSR)

Official Title

Eye Patching as a Potential Treatment Modality for and a Possible Etiological Insight on Central Serous Retinopathy

Brief Summary

      First, this study will investigate the viability of 24-hour eye patching as a potential
      treatment modality for CSR. Second, this study will assess a potential physiologic
      explanation for CSR, namely if inhibition of photic stimulation of the diseased retina will
      aid in ameliorating disease severity and disease duration.

Study Phase

Phase 1

Study Type

Interventional

Primary Outcome

Change in multi-focal ERG response and macular thickness after 24-hour patch therapy in patients with CSR

Secondary Outcome

 macular thickness

Condition

Central Serous Retinopathy (CSR)

Intervention

Eye Patching

Study Arms / Comparison Groups

 Eye Patching
Description:  Intervention

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information

Recruitment Status

Device

Estimated Enrollment

12

Start Date

November 2012

Completion Date

January 2015

Primary Completion Date

January 2015

Eligibility Criteria

        Inclusion Criteria:

          -  Adults 18 years of age and older

          -  Both males and females

          -  Patients diagnosed with active central serous retinopathy

          -  Patients who are willing to use an eye patch in the affected eye for 24 hours

          -  Patients who are able to make the follow up appointments as required by the study

        Exclusion Criteria:

          -  Individuals under 18 years of age

          -  Patients with vision less than 20/40 in the unaffected eye.

          -  Patients who are not able to undergo mfERG testing in a realiable manner.

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Gregory P Van Stavern, MD, ,

Location Countries

United States

Location Countries

United States

Administrative Informations

NCT ID

NCT02036632

Organization ID

201211016

Responsible Party

Sponsor

Study Sponsor

Washington University School of Medicine

Study Sponsor

Gregory P Van Stavern, MD, Principal Investigator, Washington University School of Medicine

Verification Date

June 2015